Skip to main content

ImmunityBio, Inc 8-K, filed Nov 9, 2026

ImmunityBio, Inc. (IBRX)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

ImmunityBio, Inc filed this 8-K on November 9, 2026.

ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year; FDA expanded ANKTIVA’s indication for BCG-unresponsive NMIBC, and Israel approval brought global approvals to 35. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits